OVAGEN - 500mg

SPECIFICATION

Product Code: OVA500D

Sequence: Glu-Asp-Leu

Molecular Formula: C15H25N3O8

Molecular Weight: 375.37 g/mol

PubChem CID: 444128

Purity: Technical / Research Grade ≥98%

Other details: No TFA Salt

Form: Lyophilized powder

Color: White

Storage temperature: -20°C

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

Ovagen is a bioregulatory peptide developed by Dr. Vladimir Khavinson. Similar to other peptides within the bioregulator class, Ovagen has been shown in research settings to cross cellular and nuclear membranes, allowing it to interact with DNA structure and influence transcriptional activity. As observed with other bioregulatory peptides, Ovagen exhibits tissue-specific activity. Its primary area of investigation relates to the regulation and normalization of liver and gastrointestinal tract function, although exploratory studies have also examined its interaction with viral replication mechanisms, including those associated with HIV.

Experimental research indicates that Ovagen supports hepatocyte proliferation and is associated with a reduction in cellular scarring and fibrotic processes that, over time, may contribute to cirrhotic changes. Within the gastrointestinal tract, Ovagen has been studied for its role in supporting the integrity of the mucosal barrier and for its association with reduced complications linked to prolonged antibiotic use, anti-inflammatory drugs, chemotherapeutic agents, and other stressors affecting intestinal tissues.

As with many bioregulatory peptides, the most pronounced effects of Ovagen have been observed in aging biological systems. Research suggests that Ovagen may influence age-related alterations in DNA organization, contributing to a transcriptional profile in liver fibroblasts and gastrointestinal mucosal cells that more closely resembles that of younger cells. This shift is associated with increased gene accessibility and enhanced cellular functional capacity.

Studies further indicate that Ovagen is generally well tolerated and may assist in normalizing liver and gastrointestinal function across a range of inflammatory and pathological research models. Its use has also been explored in postoperative contexts, during extended antibiotic exposure, in relation to mitigating side effects associated with cancer treatments, and in experimental settings focused on metabolic regulation, including diabetes-related pathways.

With respect to viral research, Ovagen has been examined for its interaction with the HIV-1 protease enzyme. HIV-1 protease plays a critical role in viral maturation by cleaving newly synthesized viral polyproteins into functional components. Without this enzymatic activity, newly formed viral particles remain non-infectious. Due to this mechanism, HIV-1 protease has long been a key target in antiviral research, and multiple protease inhibitors are currently approved for clinical use. However, the virus’s high mutation rate often leads to the development of resistance to existing inhibitors.

Research findings indicate that Ovagen functions as an inhibitor of HIV-1 protease in experimental models. Notably, Ovagen has been identified as one of the smaller peptide-based inhibitors studied, demonstrating inhibitory activity at relatively low micromolar concentrations. In contrast to several other protease inhibitors, Ovagen is highly water-soluble, a characteristic that may be relevant in formulation and experimental administration contexts. handling

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.